[Featured Stock] Why Did 'Woonpung Mulsan' in Men's Wear Hit the Upper Limit?

[Asia Economy Reporter Park Soyeon] Wonpung Mulsan is showing strong performance as its price hits the trading limit.

As of 11:48 AM on the 22nd, Wonpung Mulsan is trading at 1,820 KRW on the KOSDAQ market, up 420 KRW (30%) from the previous trading day.

Last year, Wonpung Mulsan made an equity investment in the US biopharmaceutical company Relmada.

Relmada reportedly recruited a new drug clinical expert formerly from Pfizer, leading Wonpung Mulsan to be mentioned as a Pfizer-related stock on stock forums and other platforms.

Founded in 1972, Wonpung Mulsan is a company primarily engaged in the manufacturing and sales of men's clothing, especially tailored suits, and was listed on the KOSDAQ market in 1997.

They produce high-end imported brands such as 'KINLOCH ANDERSON' and their own brand of custom tailored suits, 'BOSTON MANOR,' which are sold mainly through department stores, directly operated stores, and dealerships.

Besides fashion, the company is also investing in new business expansions such as overseas new drug development and overseas Micro-LED development.

Wonpung Mulsan has a market capitalization of 74.1 billion KRW and ranks 1,153rd on the KOSDAQ.